Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alena Laschtowitz

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Plos One|May 6, 2020
Treatment and re-treatment results of HCV patients in the DAA eraFelix Piecha, Jan-Michael Gänßler, Ann-Kathrin Ozga, et al.
Hepatology Communications|April 1, 2026
Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitisAlena Laschtowitz, Clara Vom Endt, Martin Kluge, et al.
JHEP Reports : Innovation in Hepatology|August 12, 2021
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosisAlena Laschtowitz, Kalliopi Zachou, Vasiliki Lygoura, et al.
Cell Reports. Medicine|June 20, 2024
Intergenic risk variant rs56258221 skews the fate of naive CD4<sup>+</sup> T cells via miR4464-BACH2 interplay in primary sclerosing cholangitisTobias Poch, Jonas Bahn, Christian Casar, et al.
Journal of Hepatology|March 21, 2026
Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitisYang Xu, Jan Philipp Weltzsch, Christoph Kilian, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Plos One|May 6, 2020
Treatment and re-treatment results of HCV patients in the DAA eraFelix Piecha, Jan-Michael Gänßler, Ann-Kathrin Ozga, et al.
Hepatology Communications|April 1, 2026
Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitisAlena Laschtowitz, Clara Vom Endt, Martin Kluge, et al.
JHEP Reports : Innovation in Hepatology|August 12, 2021
Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosisAlena Laschtowitz, Kalliopi Zachou, Vasiliki Lygoura, et al.
Cell Reports. Medicine|June 20, 2024
Intergenic risk variant rs56258221 skews the fate of naive CD4<sup>+</sup> T cells via miR4464-BACH2 interplay in primary sclerosing cholangitisTobias Poch, Jonas Bahn, Christian Casar, et al.
Journal of Hepatology|March 21, 2026
Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitisYang Xu, Jan Philipp Weltzsch, Christoph Kilian, et al.
Pageof 2